The NSF awarded a Phase II grant to Extend Biosciences’ PI Tarik M. Soliman, Ph.D. for a project titled “A platform technology that significantly improves drug delivery”.
News
Extend Biosciences’ Founder Laura M. Hales, Ph.D. Selected to Speak on the Plenary Panel at MALSI Day
Founder Laura M. Hales, Ph.D. was invited to speak on MALSI day’s plenary panel, “Startups that got funded in the last 18 months”. The panel also featured Kevin Bitterman (Polaris Ventures and CEO of Editas Medicine), Nancy Briefs (CEO of Infobionic), and Ashok Chander (CEO of Cellanyx Diagnostics). The 7th annual Massachusetts Life Sciences Innovation (MALSI) Day is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts. This year’s theme was “Can you still be creative?”
The Department of Defense Awards Extend Biosciences a $1M Phase II Contract
Extend Biosciences has been awarded a Phase II contract to continue working on a program of interest to the military that expands the current capabilities of the company’s platform technology.
Extend Biosciences is Accepted into LabCentral
In March 2014, Extend Biosciences moved their operations from Cambridge Biolabs to LabCentral, the premier laboratory facility for biotech startups in the heart of Kendall Square, Cambridge. Extend Biosciences was accepted into the incubator after a competitive admissions process.
Extend Biosciences Receives a Grant from the NIAAA
Extend Biosciences was awarded a Phase I SBIR grant from the National Institute on Alcohol Abuse and Alcoholism to work on a program for alcoholic liver disease (ALD) in a collaboration with fellow LabCentral resident company Advirna as well as Duke University.
MassBio Interviews Tarik Soliman, Ph.D.
MassBio interviews MassCONNECT graduate Tarik Soliman, Ph.D., Founder and CEO of Extend Biosciences to discuss the benefits of the program, the connections that were made, and the company’s experiences in the accelerator MassChallenge.
Extend Biosciences Awarded Department of Defense Contract
The Department of Defense awards a Phase I SBIR contract to Extend Biosciences to work on a program of interest to the military.
Extend Biosciences Receives National Cancer Institute Grant
The National Cancer Institute awards a Phase I SBIR grant to Extend Biosciences to work on their lead program, ghrelin for cancer cachexia.
Extend Biosciences Joins Cambridge Biolabs
Extend Biosciences exits virtual mode and joins the incubator laboratory space at Cambridge Biolabs in the heart of Kendall Square in Cambridge, MA.
Extend Biosciences Receives a Grant from the National Science Foundation
The National Science Foundation awards a Phase I SBIR grant to Extend Biosciences to develop and expand their platform technology.